跳至主要内容
临床试验/NCT05648838
NCT05648838已完成不适用

The Study for Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of Functional Tricuspid Regurgitation : Multi-center, Open Label, Single Arm, Investigator Initiated Exploratory Pilot Study

Tau-MEDICAL Co., Ltd.18 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2021年7月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
7
试验地点
18
主要终点
change of tricuspid regurgitation grade (1)

研究概览

简要总结

Pivot Balloon to monitoring acute RV failure and reduction of Functional Tricuspid Regurgitation

详细描述

The study for evaluation of safety and efficacy of Pivot Balloon to monitoring acute RV failure and reduction of Functional Tricuspid Regurgitation : multi-center, open label, single arm, investigator initiated exploratory pilot study

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult males and females aged 20 years or above
  • Target of Thoracic Surgery for TR and patients above the severe level on the criteria presented in the Classification of TR Grade based on echocardiogram, among those with TR, for whom a surgical treatment has been decided
  • An individual who voluntarily agreed to the participation in the clinical trial and signed the written consent
  • An individual who is able to understand and comply with the instructions and who can participate in the period before the clinical trial

排除标准

  • Uncontrolled hyperthyroidism
  • A recent formation of soft blood clot or embolic material
  • Uncorrected coagulopathy
  • Prohibition of anticoagulant agents
  • Previous insertion of a device such as an Implantable Cardioverter Defibrillator (ICD) or a pacemaker
  • Presence of malignant tumor or benign tumor such as myxoma in the heart
  • Presence of a symptom of active infection
  • Chronic pulmonary disease
  • Congenital tricuspid valve insufficiency
  • Pregnant or lactating mother, or a female patient planning pregnancy during the period of clinical trial, or a female not using an approved contraceptive with the possibility of pregnancy
  • Participation in another clinical trial 30 days prior to the screening
  • In addition, anyone showing a clinical finding deemed to be unsuitable for the clinical trial by the Principal Investigator or the Investigator

结局指标

主要结局

change of tricuspid regurgitation grade (1)

时间窗: immediately after the procedure

check the success of surgery /measure the size of the TR area

change of tricuspid regurgitation grade (2)

时间窗: immediately after the procedure

examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram

次要结局

  • change of tricuspid regurgitation valve hemodynamics(within 24 h of insertion)
  • evaluate the efficacy based on the function of early diagnosis (2)(within 24 h of insertion)
  • evaluate the efficacy based on the function of early diagnosis (1)(within 24 h of insertion)

研究者

发起方
Tau-MEDICAL Co., Ltd.
申办方类型
Industry
责任方
Principal Investigator
主要研究者

Seung-Whan Lee,MD,PhD

Professor

Asan Medical Center

研究点 (18)

Loading locations...

相似试验